Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Okun

Showing results (101-110 of 110) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 110 results.
American Journal of Human Genetics|February 17, 2001
Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groupsE Mignot, L Lin, W Rogers, et al.
Bioorganic & Medicinal Chemistry Letters|March 9, 2010
Synthesis of cycloalkane-annelated 3-phenylsulfonyl-pyrazolo[1,5-a]pyrimidines and their evaluation as 5-HT6 receptor antagonistsAlexandre V Ivachtchenko, Dmitri E Dmitriev, Elena S Golovina, et al.
The British Journal of Dermatology|March 28, 2019
Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trialsG B E Jemec, M M Okun, S B Forman, et al.
Orphanet Journal of Rare Diseases|May 13, 2024
Patient experiences of interprofessional collaboration and intersectoral communication in rare disease healthcare in Germany - a mixed-methods studyLaura Inhestern, Ramona Otto, Maja Brandt, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 10, 2016
Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind studyL Cai, J Gu, J Zheng, et al.
The New England Journal of Medicine|August 13, 2016
Two Phase 3 Trials of Adalimumab for Hidradenitis SuppurativaAlexa B Kimball, Martin M Okun, David A Williams, et al.
The British Journal of Dermatology|October 29, 2017
Towards global consensus on core outcomes for hidradenitis suppurativa research: an update from the HISTORIC consensus meetings I and IIL Thorlacius, A Garg, J R Ingram, et al.
Experimental Dermatology|October 15, 2020
What causes hidradenitis suppurativa ?-15 years afterChristos C Zouboulis, Farida Benhadou, Angel S Byrd, et al.
JAMA Dermatology|September 27, 2023
Outcome Measures for the Evaluation of Treatment Response in Hidradenitis Suppurativa for Clinical Practice: A HiSTORIC Consensus StatementNicole Mastacouris, Rachel Tannenbaum, Andrew Strunk, et al.
Nature Genetics|July 22, 2024
Next-generation phenotyping integrated in a national framework for patients with ultrarare disorders improves genetic diagnostics and yields new molecular findingsAxel Schmidt, Magdalena Danyel, Kathrin Grundmann, et al.
Pageof 11

Showing results (101-110 of 110) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 110 results.
American Journal of Human Genetics|February 17, 2001
Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groupsE Mignot, L Lin, W Rogers, et al.
Bioorganic & Medicinal Chemistry Letters|March 9, 2010
Synthesis of cycloalkane-annelated 3-phenylsulfonyl-pyrazolo[1,5-a]pyrimidines and their evaluation as 5-HT6 receptor antagonistsAlexandre V Ivachtchenko, Dmitri E Dmitriev, Elena S Golovina, et al.
The British Journal of Dermatology|March 28, 2019
Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trialsG B E Jemec, M M Okun, S B Forman, et al.
Orphanet Journal of Rare Diseases|May 13, 2024
Patient experiences of interprofessional collaboration and intersectoral communication in rare disease healthcare in Germany - a mixed-methods studyLaura Inhestern, Ramona Otto, Maja Brandt, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 10, 2016
Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind studyL Cai, J Gu, J Zheng, et al.
The New England Journal of Medicine|August 13, 2016
Two Phase 3 Trials of Adalimumab for Hidradenitis SuppurativaAlexa B Kimball, Martin M Okun, David A Williams, et al.
The British Journal of Dermatology|October 29, 2017
Towards global consensus on core outcomes for hidradenitis suppurativa research: an update from the HISTORIC consensus meetings I and IIL Thorlacius, A Garg, J R Ingram, et al.
Experimental Dermatology|October 15, 2020
What causes hidradenitis suppurativa ?-15 years afterChristos C Zouboulis, Farida Benhadou, Angel S Byrd, et al.
JAMA Dermatology|September 27, 2023
Outcome Measures for the Evaluation of Treatment Response in Hidradenitis Suppurativa for Clinical Practice: A HiSTORIC Consensus StatementNicole Mastacouris, Rachel Tannenbaum, Andrew Strunk, et al.
Nature Genetics|July 22, 2024
Next-generation phenotyping integrated in a national framework for patients with ultrarare disorders improves genetic diagnostics and yields new molecular findingsAxel Schmidt, Magdalena Danyel, Kathrin Grundmann, et al.
Pageof 11